References: Cannabis: harmful, hazardous and dependent use

Alcohol and Drug Foundation (ADF). Cannabinoids. ADF. 2022; Accessed September 2022. https://adf.org.au/drug-facts/amyl-nitrite/
Allsop DJ, Norberg MM, Copeland J, Fu S, Budney AJ. The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend 2011;119(1-2):123-9. https://www.ncbi.nlm.nih.gov/pubmed/21724338
Auger N, Paradis G, Low N, Ayoub A, He S, Potter BJ. Cannabis use disorder and the future risk of cardiovascular disease in parous women: a longitudinal cohort study. BMC Med 2020;18(1):328. https://www.ncbi.nlm.nih.gov/pubmed/33208143
Australian Institute of Health and Welfare (AIHW). Cannabis. Alcohol, tobacco & other drugs in Australia. Australian Government, AIHW. Updated August 2022. Accessed September 2022. https://www.aihw.gov.au/reports/alcohol/alcohol-tobacco-other-drugs-australia/contents/drug-types/cannabis#harms
Badowski S, Smith G. Cannabis use during pregnancy and postpartum. Can Fam Physician 2020;66(2):98-103. https://www.ncbi.nlm.nih.gov/pubmed/32060189
Bahji A, Stephenson C, Tyo R, Hawken ER, Seitz DP. Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis. JAMA Netw Open 2020;3(4):e202370. https://www.ncbi.nlm.nih.gov/pubmed/32271390
Bonnet U, Preuss UW. The cannabis withdrawal syndrome: current insights. Subst Abuse Rehabil 2017;8:9-37. https://www.ncbi.nlm.nih.gov/pubmed/28490916
Chocron Y, Zuber JP, Vaucher J. Cannabinoid hyperemesis syndrome. BMJ 2019;366:l4336. https://www.ncbi.nlm.nih.gov/pubmed/31324702
Duong T, Vytialingam R, O’Regan R. A brief guide to the management of alcohol and other drug withdrawal. Perth, Western Australia: Mental Health Commission; 2018.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). 25 years of monitoring and responding to new drugs in Europe. Lisbon: EMCDDA; 2022. Accessed November 2022. https://www.emcdda.europa.eu/publications/brochures/brochure-25-years-monitoring-and-responding-new-drugs-europe_en
Gates PJ, Sabioni P, Copeland J, Le Foll B, Gowing L. Psychosocial interventions for cannabis use disorder. Cochrane Database Syst Rev 2016;(5):CD005336. https://www.ncbi.nlm.nih.gov/pubmed/27149547
Gilman JM, Schuster RM, Potter KW, Schmitt W, Wheeler G, Pachas GN, et al. Effect of Medical Marijuana Card Ownership on Pain, Insomnia, and Affective Disorder Symptoms in Adults: A Randomized Clinical Trial. JAMA Netw Open 2022;5(3):e222106. https://www.ncbi.nlm.nih.gov/pubmed/35302633
Grzeskowiak LE, Grieger JA, Andraweera P, Knight EJ, Leemaqz S, Poston L, et al. The deleterious effects of cannabis during pregnancy on neonatal outcomes. Med J Aust 2020;212(11):519-24. https://www.ncbi.nlm.nih.gov/pubmed/32452049
Hoch E, Preuss UW, Ferri M, Simon R. Digital Interventions for Problematic Cannabis Users in Non-Clinical Settings: Findings from a Systematic Review and Meta-Analysis. Eur Addict Res 2016;22(5):233-42. https://www.ncbi.nlm.nih.gov/pubmed/27160333
Imtiaz S, Roerecke M, Kurdyak P, Samokhvalov AV, Hasan OSM, Rehm J. Brief Interventions for Cannabis Use in Healthcare Settings: Systematic Review and Meta-analyses of Randomized Trials. J Addict Med 2020;14(1):78-88. https://www.ncbi.nlm.nih.gov/pubmed/32012140
Insight. Cannabis Check: Ultra Brief Intervention Tool. 2018. Updated February 2022. Accessed October 2022. https://insight.qld.edu.au/shop/392-cannabis-check-ultra-brief-intervention-tool-insight-2018
Kast RE, Foley KF. Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur J Cancer Care (Engl) 2007;16(4):351-4. https://www.ncbi.nlm.nih.gov/pubmed/17587360
Manning V, Arunogiri S, Frei M, Ridley K, Mroz K, Campbell S, et al. Alcohol and other Drug Withdrawal: Practice Guidelines. 3rd ed. Richmond, Victoria: Turning Point; 2018. https://www.turningpoint.org.au/treatment/clinicians/aod-withdrawal-guidelines
Nielsen S, Gowing L, Sabioni P, Le Foll B. Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev 2019;1:CD008940. https://www.ncbi.nlm.nih.gov/pubmed/30687936
NSW Health. Drug and Alcohol Withdrawal Clinical Practice Guidelines - NSW. 2008. https://www1.health.nsw.gov.au/pds/ActivePDSDocuments/GL2008_011.pdf
NSW Health. Management of Withdrawal from Alcohol and Other Drugs_Clinical Guidance. St Leonards, NSW: NSW Ministry of Health; 2022. https://www.health.nsw.gov.au/aod/professionals/Pages/clinical-guidance.aspx
Ribeiro LI, Ind PW. Effect of cannabis smoking on lung function and respiratory symptoms: a structured literature review. NPJ Prim Care Respir Med 2016;26:16071. https://www.ncbi.nlm.nih.gov/pubmed/27763599
Silins E, Fergusson DM, Patton GC, Horwood LJ, Olsson CA, Hutchinson DM, et al. Adolescent substance use and educational attainment: An integrative data analysis comparing cannabis and alcohol from three Australasian cohorts. Drug Alcohol Depend 2015;156:90-6. https://www.ncbi.nlm.nih.gov/pubmed/26409754
Smith PH, Homish GG, Leonard KE, Collins RL. Marijuana withdrawal and aggression among a representative sample of U.S. marijuana users. Drug Alcohol Depend 2013;132(1-2):63-8. https://www.ncbi.nlm.nih.gov/pubmed/23380439
Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (Phila) 2016;54(1):1-13. https://www.ncbi.nlm.nih.gov/pubmed/26567470
van Amsterdam J, Brunt T, van den Brink W. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol 2015;29(3):254-63. https://www.ncbi.nlm.nih.gov/pubmed/25586398
Werneck MA, Kortas GT, de Andrade AG, Castaldelli-Maia JM. A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms. CNS Drugs 2018;32(12):1113-29. https://www.ncbi.nlm.nih.gov/pubmed/30361897
Wu CS, Jew CP, Lu HC. Lasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brain. Future Neurol 2011;6(4):459-80. https://www.ncbi.nlm.nih.gov/pubmed/22229018
Zahra E, Darke S, Degenhardt L, Campbell G. Rates, characteristics and manner of cannabis-related deaths in Australia 2000-2018. Drug Alcohol Depend 2020;212:108028. https://www.ncbi.nlm.nih.gov/pubmed/32370933
Zvolensky M, Farris S, Leyro S, K. L, Bernstein A, Bonn-Miller M. Cannabis: An Overview of the Empirical Literature. In: Johnson BA. Addiction Medicine: Science and Practice. 2^nd ed. Elsevier; 2020.